Clinical Trial Update: Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating atezolizumab, bevacizumab, and acetylsalicylic acid in recurrent platinum-resistant ovarian cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• Acetylsalicylic acid (Aspirin)
• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED